Carvedilol
Coreg, Coreg CR
alpha-Adrenergic Blocker
NADAC/unit
$0.0171
No Shortage
Tier 1: 389.1%
12 Manufacturers
48 ANDAs
an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stabl....
vs. brand Coreg: Generic saves up to 100% per unit
Market Intelligence
2025-08-27 Class II Recall: The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
2025-08-20 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-08-20 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-08-20 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-08-20 Class II Recall: Glenmark Pharmaceuticals Inc., USA
Generic Manufacturers
AUROBINDO PHARMA LTDCHARTWELL MOLECULAR HOLDINGS LLCGLENMARK PHARMACEUTICALS LTDIMPAX LABORATORIES INCMLV PHARMA LLCREGCON HOLDINGS LLCRISING PHARMA HOLDINGS INCRUBICON RESEARCH LTDSANDOZ INCSUN PHARMACEUTICAL INDUSTRIES INCTEVA PHARMACEUTICALS USA INCWAYLIS THERAPEUTICS LLCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.